Janssen buys rights to Hemera’s eye disease gene therapy candidate
Therapy targets CD59 protein to preserve vision in geographical atrophy patients
Read More
Tag: Hemera Biosciences
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
